Eywa FDA Thursday, June 27, 2019 0.00 Neutral

FDA Approves ACETAMINOPHEN AND CODEINE PHOSPHATE — Eywa Pharma Inc

Eywa Pharma Inc. received 180-day exclusivity for the ANDA211610 approval of acetaminophen and codeine phosphate oral dosage form on June 27, 2019, signaling heighted competitive pressure on the market and potentially catalyzing discounts for the widely used generic analgesic.

View original filing at SEC.gov →

AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day